Gossamer Bio (GOSS)
Develops inhaled seralutinib for pulmonary arterial hypertension and PH-ILD.
Something off on this page? Send us feedback.
Develops and seeks to commercialize inhaled seralutinib for PAH and PH-ILD. The clinical-stage portfolio is centered on that single program, with development and commercialization structured through a global collaboration with Chiesi.
Develops inhaled seralutinib, also called GB002, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The small-molecule candidate inhibits PDGFR, CSF1R, and c-KIT and is the sole remaining clinical-development program following a restructuring that ended other candidate programs.
Leads global development for seralutinib in PAH and PH-ILD under a collaboration with Chiesi. In the United States, the companies share commercial profit and loss while Gossamer leads commercialization in those indications; Chiesi holds exclusive commercialization rights outside the United States and pays royalties on net sales. The regulatory path depends on FDA discussions concerning an NDA supported by an adequate and well-controlled investigation plus confirmatory evidence.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | Leerink Partners | Upgrade | ||
| Mar 23, 2026 | Cantor Fitzgerald | Downgrade | ||
| Feb 24, 2026 | Wedbush | Downgrade | Target: — | Target: $1 |
| Feb 24, 2026 | Barclays | Downgrade | Target: $9 | Target: $0.30 |
| Feb 24, 2026 | Leerink Partners | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $57.0M · Total debt $39.1M · Total assets $76.9M · Shareholders' equity −$94.0M
- Revenue
- $9.2M
- Operating income
- −$26.1M
- Net income
- $16.9M
No dividends on record.
| Institutions | 76.02% | 4.65M shares | |
|---|---|---|---|
| 176 holders · as of Jun 30, 2026 | |||
| Insiders | 1.55% | 94.7K shares | |
| 7 holders · as of Jan 5, 2026 | |||
| Other | 22.43% | 1.37M shares | |
| remainder | |||
6.11M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
D. E. Shaw & Co., Inc.Institution | 8.38% | 40.96M | as of Jun 30, 2026 |
683 Capital Management, LLCInstitution | 8.02% | 39.20M | as of Jun 30, 2026 |
Deepcurrents Investment Group LLCInstitution | 7.70% | 37.67M | as of Jun 30, 2026 |
Context Capital Management, LLCInstitution | 5.92% | 28.95M | as of Jun 30, 2026 |
Worth Venture Partners, LLCInstitution | 5.12% | 25.02M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- United Therapeutics
Inhaled PAH and PH-ILD franchise led by Tyvaso
- Merck
Activin-signaling inhibitor treatment established in adult PAH
- Liquidia
Approved dry-powder treprostinil in PAH and PH-ILD
- Johnson & Johnson
PAH franchise across ERA, IP-agonist, and combination therapy
- Insmed
Once-daily inhaled treprostinil prodrug in PAH and PH-ILD studies
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gossamer Bio | $12.16 | +7.80% | $68.9M | — | — | 1.3 | −19.6% |
| United Therapeutics | $496.41 | +0.67% | $20.93B | 17.7 | 19.2 | 6.6 | −1.9% |
| Merck | $151.66 | +1.44% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Liquidia | $68.38 | +2.94% | $5.91B | 48.5 | 15.3 | 13.1 | +1,842.7% |
| Johnson & Johnson | $269.68 | +0.08% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Insmed | $121.14 | +0.12% | $26.23B | — | — | 23.1 | +296.1% |
| Median | 39.9 | 18.4 | 6.6 | +6.6% |